Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer
Aug 24, 2020
Accelerate Diagnostics today announced that Nedal Safwat has been appointed its Chief Strategy Officer. Dr. Safwat has over 20 years of experience in the medical device, in vitro diagnostics, and life sciences industries. He previously served as the Executive Director of the ID/AST Franchise at bioMerieux.joins Accelerate from BioMerieux, where he served in multiple roles over more than 11 years.
Jack Phillips, President and Chief Executive Officer of Accelerate Diagnostics, commented, “We are excited to add a leader to our team with such extensive commercial and operational experience in the microbiology diagnostics space. In this newly created position as Chief Strategy Officer, Nedal will take a leadership role in the implementation of our recently launched new product strategy and will be responsible for driving the expansion of this strategy over the long term. I am confident that his experience in the microbiology industry and commitment to growth make him a great fit for our team as we continue to execute against our long-term vision for Accelerate Diagnostics.”
“I am thrilled to join Accelerate Diagnostics, as the company plays a critical role in delivering high medical value tests that are transforming the standard of care. I look forward to working with the Accelerate team to continue delivering products that drive better clinical outcomes for patients, reinforce antibiotic stewardship, and lower the overall cost of the treatment of serious infections,” said Dr. Safwat.
Read the full press release here
- Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Individual IgM and IgG Antibody Tests
Sep 10, 2020